Combined PARP and WEE1 inhibition triggers anti-tumor immune response in BRCA1/2 wildtype triple-negative breast cancer

被引：0
作者：
Zhi Ling Teo
Mark J. O’Connor
Stephanie Versaci
Kylie A. Clarke
Emmaline R. Brown
Luke W. Percy
Keilly Kuykhoven
Christopher P. Mintoff
Peter Savas
Balaji Virassamy
Stephen J. Luen
Ann Byrne
Sneha Sant
Geoffrey J. Lindeman
Phillip K. Darcy
Sherene Loi
机构：
[1] Peter MacCallum Cancer Centre,Sir Peter MacCallum Department of Oncology
[2] The University of Melbourne,Cancer Biology and Stem Cells Division
[3] AstraZeneca Oncology,Department of Medicine
[4] The Walter and Eliza Hall Institute of Medical Research,Cancer Immunology Research
[5] University of Melbourne,undefined
[6] Peter MacCallum Cancer Centre,undefined
来源：
npj Breast Cancer | / 9卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Novel therapeutic strategies that can effectively combine with immunotherapies are needed in the treatment of triple-negative breast cancer (TNBC). We demonstrate that combined PARP and WEE1 inhibition are synergistic in controlling tumour growth in BRCA1/2 wild-type TNBC preclinical models. The PARP inhibitor (PARPi) olaparib combined with the WEE1 inhibitor (WEE1i) adavosertib triggered increases in anti-tumour immune responses, including STING pathway activation. Combinations with a STING agonist resulted in further improved durable tumour regression and significant improvements in survival outcomes in murine tumour models of BRCA1/2 wild-type TNBC. In addition, we have identified baseline tumour-infiltrating lymphocyte (TIL) levels as a potential predictive biomarker of response to PARPi, WEE1i and immunotherapies in BRCA1/2 wild-type TNBC.
引用
收藏
相关论文
共 103 条
  • [1] Bianchini G(2016)Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease Nat. Rev. Clin. Oncol. 13 674-690
  • [2] Balko JM(2017)Olaparib for metastatic breast cancer in patients with a germline BRCA mutation N. Engl. J. Med. 377 523-533
  • [3] Mayer IA(2016)Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action Sci. Transl. Med. 8 362ps317-921
  • [4] Sanders ME(2005)Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Nature 434 917-8115
  • [5] Gianni L(2006)Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition Cancer Res. 66 8109-2102
  • [6] Robson M(2020)Response of breast cancer cells to PARP inhibitors is independent of BRCA status J. Clin. Med. 9 940-1957
  • [7] Pommier Y(2020)Olaparib for metastatic castration-resistant prostate cancer N. Engl. J. Med. 382 2091-4236
  • [8] O'Connor MJ(1992)Inactivation of the p34cdc2-cyclin B complex by the human WEE1 tyrosine kinase Science 257 1955-167
  • [9] de Bono J(2012)Cyclin-dependent kinase suppression by WEE1 kinase protects the genome through control of replication initiation and nucleotide consumption Mol. Cell Biol 32 4226-867.e857
  • [10] Farmer H(2019)Differential activity of ATR and WEE1 inhibitors in a highly sensitive subpopulation of DLBCL linked to replication stress Cancer Res. 79 3762-319
12345678910